SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets USFDA nod for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride tablets

30 May 2026 Evaluate

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g, indicated for the cleansing of the colon as a preparation for colonoscopy in adults. 

Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, 1.479 g/0.225 g/0.188 g is bioequivalent to the reference listed drug (RLD), Sutab Tablets, 1.479 g/0.225 g/0.188 g of Azurity Pharmaceuticals, Inc. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity. This product will be manufactured at Lupin’s Nagpur facility in India.

Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets (RLD Sutab) had an estimated annual sale of $132.8 million in the U.S. (IQVIA MAT March 2026).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2268.10 19.40 (0.86%)
05-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.55
Dr. Reddys Lab 1277.80
Cipla 1400.70
Zydus Lifesciences 1088.90
Lupin 2268.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×